{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:57:34Z","timestamp":1773154654606,"version":"3.50.1"},"reference-count":99,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1704,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Depress. Anxiety"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1002\/da.20769","type":"journal-article","created":{"date-parts":[[2011,1,10]],"date-time":"2011-01-10T20:36:16Z","timestamp":1294691776000},"page":"76-87","source":"Crossref","is-referenced-by-count":34,"title":["Advances in pharmacotherapy for pediatric anxiety disorders"],"prefix":"10.1155","volume":"28","author":[{"given":"Moira","family":"Rynn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Puliafico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Heleniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranav","family":"Rikhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kareem","family":"Ghalib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilary","family":"Vidair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,1,10]]},"reference":[{"key":"10.1002\/da.20769-BIB1|cit1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/archpsyc.1987.01800130081010","article-title":"DSM-III disorders in preadolescent children. Prevalence in a large sample from the general population","volume":"44","author":"Anderson","year":"1987","journal-title":"Arch Gen Psychiatry"},{"key":"10.1002\/da.20769-BIB2|cit2","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1097\/01.chi.0000172552.41596.6f","article-title":"10-year research update review: the epidemiology of child and adolescent psychiatric disorders: I. Methods and public health burden","volume":"44","author":"Costello","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1002\/da.20769-BIB3|cit3","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","article-title":"Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"10.1002\/da.20769-BIB4|cit4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/15374410701817956","article-title":"Evidence-based psychosocial treatments for child and adolescent obsessive-compulsive disorder","volume":"37","author":"Barrett","year":"2008","journal-title":"J Clin Child Adolesc Psychol"},{"key":"10.1002\/da.20769-BIB5|cit5","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/archpsyc.1991.01810270028003","article-title":"Traumatic events and posttraumatic stress disorder in an urban population of young adults","volume":"48","author":"Breslau","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"10.1002\/da.20769-BIB6|cit6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1037\/h0080183","article-title":"The impact of exposure to crime and violence on urban youth","volume":"66","author":"Berman","year":"1996","journal-title":"Am J Orthopsychiatry"},{"key":"10.1002\/da.20769-BIB7|cit7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.chi.0000246070.23695.06","article-title":"Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders","volume":"46","author":"Connolly","year":"2007","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1002\/da.20769-BIB8|cit8","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/00004583-199207000-00003","article-title":"Chronic course of anxiety disorders in children and adolescents","volume":"31","author":"Keller","year":"1992","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1002\/da.20769-BIB9|cit9","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1037\/0033-2909.111.2.244","article-title":"Comorbidity of anxiety and depression in children and adolescents","volume":"111","author":"Brady","year":"1992","journal-title":"Psychol Bull"},{"key":"10.1002\/da.20769-BIB10|cit10","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.chc.2005.06.003","article-title":"The developmental epidemiology of anxiety disorders: phenomenology, prevalence, and comorbidity","volume":"14","author":"Costello","year":"2005","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"10.1002\/da.20769-BIB11|cit11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/archpsyc.55.1.56","article-title":"The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders","volume":"55","author":"Pine","year":"1998","journal-title":"Arch Gen Psychiatry"},{"key":"10.1002\/da.20769-BIB12|cit12","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/archpsyc.64.5.566","article-title":"Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions","volume":"64","author":"Compton","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1002\/da.20769-BIB13|cit13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1017\/S0033291706009147","article-title":"Anxiety disorders and suicidal behaviours in adolescence and young adulthood: findings from a longitudinal study","volume":"37","author":"Boden","year":"2007","journal-title":"Psychol Med"},{"key":"10.1002\/da.20769-BIB14|cit14","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1176\/appi.ajp.158.12.2008","article-title":"Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder","volume":"158","author":"Rynn","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.20769-BIB15|cit15","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1176\/appi.ajp.164.2.290","article-title":"Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials","volume":"164","author":"Rynn","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.20769-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/archpsyc.61.11.1153","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder","volume":"61","author":"Wagner","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"10.1002\/da.20769-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.biopsych.2007.02.025","article-title":"A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder","volume":"62","author":"March","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1002\/da.20769-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1097\/chi.0b013e318154bb57","article-title":"SET-C versus fluoxetine in the treatment of childhood social phobia","volume":"46","author":"Beidel","year":"2007","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1002\/da.20769-BIB19|cit19","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/chi.0b013e3180547105","article-title":"A pilot randomized controlled trial of combined trauma-focused CBT and sertraline for childhood PTSD symptoms","volume":"46","author":"Cohen","year":"2007","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1002\/da.20769-BIB20|cit20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00004583-199201000-00008","article-title":"Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder-a multicenter trial","volume":"31","author":"DeVeaugh-Geiss","year":"1992","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1002\/da.20769-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1001\/jama.280.20.1752","article-title":"Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial","volume":"280","author":"March","year":"1998","journal-title":"J Am Med Assoc"},{"key":"10.1002\/da.20769-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/00004583-200110000-00011","article-title":"Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder","volume":"40","author":"Cook","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1002\/da.20769-BIB23|cit23","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00004583-200107000-00011","article-title":"Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial","volume":"40","author":"Geller","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1002\/da.20769-BIB24|cit24","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4088\/JCP.v63n0113","article-title":"A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder","volume":"63","author":"Liebowitz","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/da.20769-BIB25|cit25","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00004583-200102000-00017","article-title":"Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial","volume":"40","author":"Riddle","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1002\/da.20769-BIB26|cit26","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1089\/104454603322126313","article-title":"Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials?","volume":"13","author":"Geller","year":"2003","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1002\/da.20769-BIB27|cit27","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1097\/01.chi.0000138356.29099.f1","article-title":"Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial","volume":"43","author":"Geller","year":"2004","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1002\/da.20769-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1001\/jama.292.16.1969","article-title":"Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: The Pediatric OCD Treatment Study (POTS) randomized controlled trial","volume":"292","author":"March","year":"2004","journal-title":"J Am Med Assoc"},{"key":"10.1002\/da.20769-BIB29|cit29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1192\/bjp.138.2.110","article-title":"School phobia: a therapeutic trial with clomipramine and short-term outcome","volume":"138","author":"Berney","year":"1981","journal-title":"Br J Psychiatry"},{"key":"10.1002\/da.20769-BIB30|cit30","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00004583-199009000-00016","article-title":"Comparative studies of pharmacotherapy for school refusal","volume":"29","author":"Bernstein","year":"1990","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1002\/da.20769-BIB31|cit31","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1001\/archpsyc.1971.01750150012002","article-title":"Controlled imipramine treatment of school phobia","volume":"25","author":"Gittelman-Klein","year":"1971","journal-title":"Arch Gen Psychiatry"},{"key":"10.1002\/da.20769-BIB32|cit32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00004583-199201000-00005","article-title":"Imipramine treatment of children with separation anxiety disorder","volume":"31","author":"Klein","year":"1992","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1002\/da.20769-BIB33|cit33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00004583-200102000-00014","article-title":"School refusal in children and adolescents: a review of the past 10 years","volume":"40","author":"King","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1002\/da.20769-BIB34|cit34","first-page":"42","article-title":"School phobia: controlled imipramine treatment","volume":"115","author":"Gittelman-Klein","year":"1971","journal-title":"Calif Med"},{"key":"10.1002\/da.20769-BIB35|cit35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00004583-199201000-00005","article-title":"Imipramine treatment of children with separation anxiety disorder","volume":"31","author":"Klein","year":"1992","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1002\/da.20769-BIB36|cit36","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1192\/bjp.138.2.110","article-title":"School phobia: a therapeutic trial with clomipramine and short-term outcome","volume":"138","author":"Berney","year":"1981","journal-title":"Br J Psychiatry"},{"key":"10.1002\/da.20769-BIB37|cit37","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00004583-199009000-00016","article-title":"Comparative studies of pharmacotherapy for school refusal","volume":"29","author":"Bernstein","year":"1990","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1002\/da.20769-BIB38|cit38","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00004583-200003000-00008","article-title":"Imipramine plus cognitive-behavioral therapy in the treatment of school refusal","volume":"39","author":"Bernstein","year":"2000","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1002\/da.20769-BIB39|cit39","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00004583-200102000-00015","article-title":"Treatment of school refusal: one-year follow-up","volume":"40","author":"Bernstein","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1002\/da.20769-BIB40|cit40","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1056\/NEJMoa0804633","article-title":"Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety","volume":"359","author":"Walkup","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1002\/da.20769-BIB41|cit41","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/archpsyc.61.10.1005","article-title":"Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia","volume":"61","author":"Davidson","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"10.1002\/da.20769-BIB42|cit42","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1176\/appi.ajp.162.1.151","article-title":"Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder","volume":"162","author":"Foa","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.20769-BIB43|cit43","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1192\/bjp.162.6.776","article-title":"Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto","volume":"162","author":"Marks","year":"1993","journal-title":"Br J Psychiatry"},{"key":"10.1002\/da.20769-BIB44|cit44","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0006-3223(02)01507-X","article-title":"The role of glutamate and gamma-aminobutyric acid in fear extinction: clinical implications for exposure therapy","volume":"52","author":"Davis","year":"2002","journal-title":"Biol Psychiatry"},{"key":"10.1002\/da.20769-BIB45|cit45","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1037\/0735-7044.117.2.341","article-title":"Effects of D-cycloserine on extinction of conditioned freezing","volume":"117","author":"Ledgerwood","year":"2003","journal-title":"Behav Neurosci"},{"key":"10.1002\/da.20769-BIB46|cit46","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1523\/JNEUROSCI.22-06-02343.2002","article-title":"Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats","volume":"22","author":"Walker","year":"2002","journal-title":"J Neurosci"},{"key":"10.1002\/da.20769-BIB47|cit47","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/archpsyc.61.11.1136","article-title":"Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear","volume":"61","author":"Ressler","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"10.1002\/da.20769-BIB48|cit48","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1001\/archpsyc.63.3.298","article-title":"Augmentation of exposure therapy with D-cycloserine for social anxiety disorder","volume":"63","author":"Hofmann","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1002\/da.20769-BIB49|cit49","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.biopsych.2007.11.011","article-title":"A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder","volume":"63","author":"Guastella","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1002\/da.20769-BIB50|cit50","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.biopsych.2009.07.036","article-title":"Efficacy of D-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder","volume":"67","author":"Otto","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1002\/da.20769-BIB51|cit51","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1176\/appi.ajp.2007.07050776","article-title":"Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder","volume":"165","author":"Wilhelm","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.20769-BIB52|cit52","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.biopsych.2006.12.020","article-title":"D-cycloserine augmented exposure therapy for obsessive-compulsive disorder","volume":"62","author":"Kushner","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1002\/da.20769-BIB53|cit53","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/YIC.0b013e32819f8480","article-title":"D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder","volume":"22","author":"Storch","year":"2007","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1002\/da.20769-BIB54|cit54","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jpsychires.2006.05.006","article-title":"A randomized controlled trial of the effect of D-cycloserine on exposure therapy for spider fear","volume":"41","author":"Guastella","year":"2007","journal-title":"J Psychiatr Res"},{"key":"10.1002\/da.20769-BIB55|cit55","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.biopsych.2008.01.012","article-title":"A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy","volume":"63","author":"Norberg","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1002\/da.20769-BIB56|cit56","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.brat.2006.07.005","article-title":"A randomized controlled trial of the effect of D-cycloserine on extinction and fear conditioning in humans","volume":"45","author":"Guastella","year":"2007","journal-title":"Behav Res Ther"},{"key":"10.1002\/da.20769-BIB57|cit57","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1527-3458.2006.00208.x","article-title":"Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine","volume":"12","author":"Hofmann","year":"2006","journal-title":"CNS Drug Rev"},{"key":"10.1002\/da.20769-BIB58|cit58","article-title":"A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder","author":"Storch","journal-title":"Biol Psychiatry"},{"key":"10.1002\/da.20769-BIB59|cit59","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.biopsych.2006.03.084","article-title":"Effects of D-cycloserine on extinction: translation from preclinical to clinical work","volume":"60","author":"Davis","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1002\/da.20769-BIB60|cit60","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/sj.bjp.0703424","article-title":"Effects of riluzole on electrically evoked neurotransmitter release","volume":"130","author":"Jehle","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1002\/da.20769-BIB61|cit61","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1046\/j.1460-9568.2000.00242.x","article-title":"Riluzole inhibits the persistent sodium current in mammalian CNS neurons","volume":"12","author":"Urbani","year":"2000","journal-title":"Eur J Neurosci"},{"key":"10.1002\/da.20769-BIB62|cit62","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00213-003-1396-z","article-title":"Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder","volume":"167","author":"Coric","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1002\/da.20769-BIB63|cit63","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4088\/JCP.v68n0123f","article-title":"Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with trichotillomania","volume":"68","author":"Coric","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/da.20769-BIB64|cit64","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/01.jcp.0000245567.29531.d6","article-title":"Beneficial effects of the glutamate-modulating agent riluzole on disordered eating and pathological skin-picking behaviors","volume":"26","author":"Sasso","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"10.1002\/da.20769-BIB65|cit65","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/JCP.0b013e3181727548","article-title":"Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a series of 13 cases, with long-term follow-up","volume":"28","author":"Pittenger","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1002\/da.20769-BIB66|cit66","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2005.04.043","article-title":"Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial","volume":"58","author":"Coric","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1002\/da.20769-BIB67|cit67","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1176\/appi.ajp.162.12.2379","article-title":"Open-label trial of riluzole in generalized anxiety disorder","volume":"162","author":"Mathew","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.20769-BIB68|cit68","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.biopsych.2007.09.012","article-title":"Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder","volume":"63","author":"Mathew","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1002\/da.20769-BIB69|cit69","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1176\/appi.ajp.162.12.2379","article-title":"Open-label trial of riluzole in generalized anxiety disorder","volume":"162","author":"Mathew","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.20769-BIB70|cit70","first-page":"25","article-title":"Riluzole effective for generalized anxiety disorder","volume":"12","author":"Ginsberg","year":"2005","journal-title":"Prim Psychiatry"},{"key":"10.1002\/da.20769-BIB71|cit71","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1089\/cap.2007.0021","article-title":"An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder","volume":"17","author":"Grant","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1002\/da.20769-BIB72|cit72","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.neuropharm.2008.04.003","article-title":"Memantine protects against amphetamine derivatives-induced neurotoxic damage in rodents","volume":"54","author":"Chipana","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1002\/da.20769-BIB73|cit73","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1037\/a0016402","article-title":"The combined effects of memantine and fluoxetine on an animal model of obsessive compulsive disorder","volume":"17","author":"Wald","year":"2009","journal-title":"Exp Clin Psychopharmacol"},{"key":"10.1002\/da.20769-BIB74|cit74","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/JCP.0b013e3181c856de","article-title":"A single-blinded case-control study of memantine in severe obsessive-compulsive disorder","volume":"30","author":"Stewart","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"10.1002\/da.20769-BIB75|cit75","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.pnpbp.2006.04.013","article-title":"Memantine augmentation for refractory obsessive-compulsive disorder","volume":"30","author":"Pasquini","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1002\/da.20769-BIB76|cit76","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/JCP.0b013e318192e9a4","article-title":"Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial","volume":"29","author":"Aboujaoude","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"10.1002\/da.20769-BIB77|cit77","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1176\/appi.ajp.162.11.2191-a","article-title":"Memantine for treatment-resistant OCD","volume":"162","author":"Poyurovsky","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.20769-BIB78|cit78","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1176\/appi.ajp.2008.08091427","article-title":"Memantine as an augmenting agent for severe pediatric OCD","volume":"166","author":"Hezel","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.20769-BIB79|cit79","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/WNF.0b013e318184fae2","article-title":"Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation","volume":"32","author":"Keck","year":"2009","journal-title":"Clin Neuropharmacol"},{"key":"10.1002\/da.20769-BIB80|cit80","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/jcp.0b013e318059361a","article-title":"The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence","volume":"27","author":"Mula","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1002\/da.20769-BIB81|cit81","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1176\/appi.ajp.160.3.533","article-title":"Pregabalin in generalized anxiety disorder: a placebo-controlled trial","volume":"160","author":"Pande","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.20769-BIB82|cit82","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00004714-200306000-00005","article-title":"A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder","volume":"23","author":"Feltner","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"10.1002\/da.20769-BIB83|cit83","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1212\/WNL.53.7.1503","article-title":"Psychiatric adverse events during vigabatrin therapy","volume":"53","author":"Levinson","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/da.20769-BIB84|cit84","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1111\/j.1528-1167.2007.01262.x","article-title":"Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam","volume":"48","author":"Mula","year":"2007","journal-title":"Epilepsia"},{"key":"10.1002\/da.20769-BIB85|cit85","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/371702a0","article-title":"\u03b2-Adrenergic activation and memory for emotional events","volume":"371","author":"Cahill","year":"1994","journal-title":"Nature"},{"key":"10.1002\/da.20769-BIB86|cit86","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0006-3223(01)01279-3","article-title":"Pilot study of secondary prevention of posttraumatic stress disorder with propranolol","volume":"51","author":"Pitman","year":"2002","journal-title":"Biol Psychiatry"},{"key":"10.1002\/da.20769-BIB87|cit87","first-page":"37","volume-title":"Focus on Posttraumatic Stress Disorder Research","author":"Taylor","year":"2005"},{"key":"10.1002\/da.20769-BIB88|cit88","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1023\/A:1020145610914","article-title":"Propranolol for reemergent posttraumatic stress disorder following an event of retraumatization: a case study","volume":"15","author":"Taylor","year":"2002","journal-title":"J Trauma Stress"},{"key":"10.1002\/da.20769-BIB89|cit89","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jpsychires.2007.05.006","article-title":"Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress","volume":"42","author":"Brunet","year":"2008","journal-title":"J Psychiatr Res"},{"key":"10.1002\/da.20769-BIB90|cit90","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0006-3223(03)00412-8","article-title":"Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma","volume":"54","author":"Vaiva","year":"2003","journal-title":"Biol Psychiatry"},{"key":"10.1002\/da.20769-BIB91|cit91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jme.2008.024752","article-title":"Propranolol, post-traumatic stress disorder and narrative identity","volume":"34","author":"Bell","year":"2008","journal-title":"J Med Ethics: J Insitute Med Ethics"},{"key":"10.1002\/da.20769-BIB92|cit92","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/S0006-3223(99)00248-6","article-title":"The treatment of anxiety disorders in children and adolescents","volume":"46","author":"Labellarte","year":"1999","journal-title":"Biol Psychiatry"},{"key":"10.1002\/da.20769-BIB93|cit93","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0031-3955(05)70069-9","article-title":"Pharmacologic treatment for children and adolescents with anxiety disorders","volume":"45","author":"Birmaher","year":"1998","journal-title":"Pediatr Clin North Am"},{"key":"10.1002\/da.20769-BIB94|cit94","unstructured":"FDA 2007 http:\/\/www.fda.gov.downloads\/Drugs\/DrugSafety\/InformationbyDrugClass\/ucm100211.pdf"},{"key":"10.1002\/da.20769-BIB95|cit95","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1089\/104454602760386888","article-title":"Treating children and adolescents with selective serotonin reuptake inhibitors: how long is appropriate?","volume":"12","author":"Pine","year":"2002","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1002\/da.20769-BIB96|cit96","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/09540260220132671","article-title":"Combining medication and psychosocial treatments: an evidence-based medicine approach","volume":"14","author":"March","year":"2002","journal-title":"Int Rev Psychiatry"},{"key":"10.1002\/da.20769-BIB97|cit97","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/sj.npp.1301569","article-title":"Anxiety as a developmental disorder","volume":"33","author":"Leonardo","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/da.20769-BIB98|cit98","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/npp.2008.113","article-title":"Challenges in developing novel treatments for childhood disorders: lessons from research on anxiety","volume":"34","author":"Pine","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/da.20769-BIB99|cit99","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00213-006-0542-9","article-title":"fMRI predictors of treatment outcome in pediatric anxiety disorders","volume":"191","author":"McClure","year":"2007","journal-title":"Psychopharmacology"}],"container-title":["Depression and Anxiety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fda.20769","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/da.20769\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T22:39:31Z","timestamp":1712097571000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/da.20769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"URL":"https:\/\/doi.org\/10.1002\/da.20769","relation":{},"ISSN":["1091-4269"],"issn-type":[{"value":"1091-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}